BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 15, 2009
View Archived Issues
Cempra Closes $46M Series C for Trials of Two Antibiotics
Cempra Pharmaceuticals Inc. raised $46 million in a Series C financing to continue clinical trials with the two antibiotic programs it licensed three years ago from Optimer Pharmaceuticals Inc. (BioWorld Today)
Read More
Economic Downturn Sheds Light on Biotech Value to Communities
Read More
Study: Beta-Catenin is Culprit in Colon Cancer, Not Polyps
Read More
UCB's Anti-TNF Cimzia Gets FDA Nod; Enters Crowded RA Space
Read More
Corrections & Clarifications
Read More
Other News To Note
Read More
Clinic Roundup
Read More